Medicenna Up 7% As Presents "Compelling Results" From ABILITY-1 Clinical Trial at AACR Meeting

MT NewswiresApr 28 10:42 ET

Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting

GlobeNewswireMar 26 07:00 ET

Medicenna Reports MDNA11's Compelling Anti-Cancer Activity Is Associated With Significant Expansion of 'Stem-Like' Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

GlobeNewswireFeb 25 07:00 ET

Medicenna Therapeutics up 12% Following Third-Quarter Results

MT NewswiresFeb 13 11:21 ET

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

GlobeNewswireFeb 13 10:28 ET

Medicenna Therapeutics Corp: INTERIM FINANCIAL STATEMENTSREPORT LETTER FROM FOREIGN ISSUER

SEDARFeb 12 21:00 ET · Announcements